Search Results - "Hockaday, Anna"

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial by Jackson, Graham H, Pawlyn, Charlotte, Cairns, David A, de Tute, Ruth M, Hockaday, Anna, Collett, Corinne, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Drayson, Mark T, Gregory, Walter M, Kaiser, Martin F, Owen, Roger G, Davies, Faith E, Morgan, Gareth J

“…Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral…”
Get full text

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial by Cook, Gordon, Prof, Ashcroft, A John, MBBChir, Cairns, David A, PhD, Williams, Cathy D, MBBS, Brown, Julia M, PhD, Cavenagh, Jamie D, MBBS, Snowden, John A, MBBS, Parrish, Christopher, MBBS, Yong, Kwee, MBBS, Cavet, Jim, MBBChir, Hunter, Hannah, MBBS, Bird, Jenny M, MBBS, Pratt, Guy, MBBS, Chown, Sally, MBBS, Heartin, Ernest, MBBS, O'Connor, Sheila, PhD, Drayson, Mark T, PhD, Hockaday, Anna, MSc, Morris, Treen C M, MD

“…Summary Background The Myeloma X trial previously reported improved durability of response (time to disease progression) in patients with relapsed multiple…”
Get full text

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia by Howard, Dena R, Hockaday, Anna, Brown, Julia M, Gregory, Walter M, Todd, Susan, Munir, Tahla, Oughton, Jamie B, Dimbleby, Claire, Hillmen, Peter

“…The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to…”
Get full text

Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project by Wilson, Nina, Biggs, Katie, Bowden, Sarah, Brown, Julia, Dimairo, Munyaradzi, Flight, Laura, Hall, Jamie, Hockaday, Anna, Jaki, Thomas, Lowe, Rachel, Murphy, Caroline, Pallmann, Philip, Pilling, Mark A, Snowdon, Claire, Sydes, Matthew R, Villar, Sofía S, Weir, Christopher J, Welburn, Jessica, Yap, Christina, Maier, Rebecca, Hancock, Helen, Wason, James M S

“…Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials. An important barrier to further increased use is a…”
Get full text

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial by Royle, Kara-Louise, Coulson, Amy Beth, Ramasamy, Karthik, Cairns, David A, Hockaday, Anna, Quezada, Sergio, Drayson, Mark, Kaiser, Martin, Owen, Roger, Auner, Holger W, Cook, Gordon, Meads, David, Olivier, Catherine, Barnard, Lorna, Lambkin, Rhiannon, Paterson, Andrea, Dawkins, Bryony, Chapman, Mike, Pratt, Guy, Popat, Rakesh, Jackson, Graham, Bygrave, Ceri, Sive, Jonathan, de Tute, Ruth, Chantry, Andrew, Parrish, Christopher, Cook, Mark, Asher, Samir, Yong, Kwee

“…IntroductionMultiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be…”
Get full text

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial by Coulson, Amy Beth, Royle, Kara-Louise, Pawlyn, Charlotte, Cairns, David A, Hockaday, Anna, Bird, Jennifer, Bowcock, Stella, Kaiser, Martin, de Tute, Ruth, Rabin, Neil, Boyd, Kevin, Jones, John, Parrish, Christopher, Gardner, Hayley, Meads, David, Dawkins, Bryony, Olivier, Catherine, Henderson, Rowena, Best, Phillip, Owen, Roger, Jenner, Matthew, Kishore, Bhuvan, Drayson, Mark, Jackson, Graham, Cook, Gordon

“…IntroductionMultiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the…”
Get full text

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial by Striha, Alina, Ashcroft, A John, Hockaday, Anna, Cairns, David A, Boardman, Karen, Jacques, Gwen, Williams, Cathy, Snowden, John A, Garg, Mamta, Cavenagh, Jamie, Yong, Kwee, Drayson, Mark T, Owen, Roger, Cook, Mark, Cook, Gordon

“…Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in…”
Get full text

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial by Oughton, Jamie B, Collett, Laura, Howard, Dena R, Hockaday, Anna, Munir, Talha, McMahon, Kathryn, McParland, Lucy, Dimbleby, Claire, Phillips, David, Rawstron, Andy C, Hillmen, Peter

“…Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor…”
Get full text

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial by Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Hockaday, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, Morgan, Gareth J

“…Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell…”
Get full text

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease by Munir, Talha, Cairns, David A., Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew, Paneesha, Shankara, Fox, Christopher P., Eyre, Toby A., Forconi, Francesco, Elmusharaf, Nagah, Kennedy, Ben, Gribben, John, Pemberton, Nicholas, Sheehy, Oonagh, Preston, Gavin, Schuh, Anna, Walewska, Renata, Duley, Lelia, Howard, Dena, Hockaday, Anna, Jackson, Sharon, Greatorex, Natasha, Girvan, Sean, Bell, Sue, Brown, Julia M., Webster, Nichola, Dalal, Surita, de Tute, Ruth, Rawstron, Andrew, Patten, Piers E.M., Hillmen, Peter

“…Among patients with previously untreated chronic lymphocytic leukemia, ibrutinib–venetoclax therapy with treatment duration guided by measurable residual…”
Get full text

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk by de Tute, Ruth M, Pawlyn, Charlotte, Cairns, David A, Davies, Faith E, Menzies, Tom, Rawstron, Andy, Jones, John R, Hockaday, Anna, Henderson, Rowena, Cook, Gordon, Drayson, Mark T, Jenner, Matthew W, Kaiser, Martin F, Gregory, Walter M, Morgan, Gareth J, Jackson, Graham H, Owen, Roger G

“…Minimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when…”
Get full text

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial by Hillmen, Peter, Pitchford, Alexandra, Bloor, Adrian, Broom, Angus, Young, Moya, Kennedy, Ben, Walewska, Renata, Furtado, Michelle, Preston, Gavin, Neilson, Jeffrey R, Pemberton, Nicholas, Sidra, Gamal, Morley, Nicholas, Cwynarski, Kate, Schuh, Anna, Forconi, Francesco, Elmusharaf, Nagah, Paneesha, Shankara, Fox, Christopher P, Howard, Dena R, Hockaday, Anna, Brown, Julia M, Cairns, David A, Jackson, Sharon, Greatorex, Natasha, Webster, Nichola, Shingles, Jane, Dalal, Surita, Patten, Piers E M, Allsup, David, Rawstron, Andrew, Munir, Talha

“…The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which…”
Get full text

Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma by Bygrave, Ceri, Pawlyn, Charlotte, Davies, Faith, Craig, Zoe, Cairns, David, Hockaday, Anna, Jenner, Matthew, Cook, Gordon, Drayson, Mark, Owen, Roger, Gregory, Walter, Morgan, Gareth, Jackson, Graham, Kaiser, Martin

“…Summary Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome…”
Get full text

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials by Bradbury, Charlotte A., Craig, Zoe, Cook, Gordon, Pawlyn, Charlotte, Cairns, David A., Hockaday, Anna, Paterson, Andrea, Jenner, Matthew W., Jones, John R., Drayson, Mark T., Owen, Roger G., Kaiser, Martin F., Gregory, Walter M., Davies, Faith E., Child, J. Anthony, Morgan, Gareth J., Jackson, Graham H.

“…Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking…”
Get full text

TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia by Bomben, Riccardo, Rossi, Francesca Maria, Vit, Filippo, Bittolo, Tamara, D'Agaro, Tiziana, Zucchetto, Antonella, Tissino, Erika, Pozzo, Federico, Vendramini, Elena, Degan, Massimo, Zaina, Eva, Cattarossi, Ilaria, Varaschin, Paola, Nanni, Paola, Berton, Michele, Braida, Alessandra, Polesel, Jerry, Cohen, Jared A, Santinelli, Enrico, Biagi, Annalisa, Gentile, Massimo, Morabito, Fortunato, Fronza, Gilberto, Pozzato, Gabriele, D'Arena, Giovanni, Olivieri, Jacopo, Bulian, Pietro, Pepper, Chris, Hockaday, Anna, Schuh, Anna, Hillmen, Peter, Rossi, Davide, Chiarenza, Annalisa, Zaja, Francesco, Di Raimondo, Francesco, Del Poeta, Giovanni, Gattei, Valter

“…In chronic lymphocytic leukemia (CLL), mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the…”
Get full text

Redefining nonmeasurable multiple myeloma using mass spectrometry by Giles, Hannah V., Cook, Mark A., Drayson, Mark Trehane, Cook, Gordon, Wright, Nicola Jane, North, Simon John, Harding, Stephen, Cairns, David A., Hockaday, Anna, Kaiser, Martin F., Moss, Paul, Davies, Faith E., Morgan, Gareth J., Jackson, Graham, Pratt, Guy

Get full text

Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial by Munir, Talha, Emmerson, Jake, Hockaday, Anna, Oughton, Jamie B., Howard, Dena, Phillips, David, Neilson, Jeff, Pemberton, Nicholas, Paneesha, Shankara, Kennedy, Ben, Rawstron, Andy, Hillmen, Peter

“…Summary The GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In chronic lymphocytic leukaemia (CLL) (GALACTIC) was a seamless phase II/III…”
Get full text

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients by Sarma, Anita, Evans, Charlotte, Dalal, Surita, Webster, Nichola, Rawstron, Andy, Shingles, Jane, Newton, Darren, Cairns, David Allan, Glover, Paul, Grand, Thomas, Warren, Helen, Bell, Sue, Girvan, Sean, Greatorex, Natasha, Hockaday, Anna, Jackson, Sharon, Phillips, David, Stones, David, Allsup, David, Bloor, Adrian John Clifton, Varghese, Abraham Mullasseril, Munir, Talha, Hillmen, Peter

“…Background The NCRI FLAIR trial confirmed ibrutinib + rituximab (IR) improved progression free survival (PFS) over FCR in untreated CLL. Durable responses are…”
Get full text

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact by Dalal, Surita, Sarma, Anita, Shingles, Jane, Glover, Paul, Warren, Helen, Grand, Thomas, Webster, Nichola, Rawstron, Andy, Newton, Darren, Bell, Sue, Cairns, David Allan, Girvan, Sean, Greatorex, Natasha, Hockaday, Anna, Jackson, Sharon, Phillips, David, Stones, David, Allsup, David, Bloor, Adrian John Clifton, Varghese, Abraham Mullasseril, Munir, Talha, Hillmen, Peter

“…Introduction: Recent studies using next generation sequencing have revealed recurrent mutated genes in CLL are associated with clinical outcome. We assessed…”
Get full text

Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD) by Cook, Gordon, Ashcroft, A J, Senior, Ethan R, Olivier, Catherine, Hockaday, Anna, Richards, Jeanine, Cavenagh, James D., Snowden, John, Drayson, Mark, de Tute, Ruth M, Owen, Roger, Yong, Kwee, Garg, Mamta, Boyd, Kevin, Sati, Hamdi, Gillson, Sharon, Cook, Mark, Cairns, David Allan, Parrish, Christopher

“…Introduction: sASCT in multiple myeloma (MM) induces superior durability of response over non-transplant consolidation 1. Currently there is no prospective…”
Get full text